Management of Elevated Blood Pressure with Epigastric Pain

Introduction to Epigastric Pain and Hypertension

Epigastric pain in the context of hypertension can represent acute myocardial ischemia or infarction, and case reports have documented that nifedipine (a related calcium channel blocker) caused epigastric pain, dizziness, nausea, diaphoresis, and ECG changes consistent with cardiac ischemia 1.
Rapid blood pressure reduction with any vasodilator can precipitate or worsen myocardial ischemia through coronary hypoperfusion, particularly if the patient has underlying coronary artery disease 1, 2.

Obtain an immediate 12-lead ECG to evaluate for ST-segment changes, T-wave abnormalities, or other signs of acute coronary syndrome 1.
Check cardiac troponin levels, as elevated troponin-I is a prognostic factor for major adverse cardiac events in patients with hypertensive presentations 3.
Assess for other causes of epigastric pain including aortic dissection, perforated viscus, or acute pancreatitis 1.

The American Heart Association recommends IV labetalol or nicardipine with magnesium for pre-eclampsia or eclampsia with hypertensive crisis 4, 5.
The European Society of Cardiology recommends nicardipine 5-15 mg/hr IV as a first-line parenteral agent for hypertensive emergencies with confirmed end-organ damage (excluding acute coronary syndrome) 2.

Asymptomatic hypertension in the emergency department does not benefit from acute pharmacologic intervention and may increase the risk of harm 1.
Blood pressure naturally decreases by approximately 6% (11 mmHg systolic, 8 mmHg diastolic) without pharmaceutical intervention after a short observation period 1.
There is no evidence that treating asymptomatic elevated blood pressure in the ED improves outcomes, and rapid lowering can cause organ hypoperfusion 1, 2.

Unpredictable blood pressure drops can lead to organ hypoperfusion, particularly cerebral and coronary hypoperfusion 2.
Reflex tachycardia from vasodilation can increase myocardial oxygen demand, worsening ischemia if present 1, 2.
The FDA specifically warns about safety concerns with rapid-acting calcium channel blockers in uncontrolled settings 2.